Australia markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3358+0.0207 (+6.57%)
At close: 04:00PM EDT
0.3640 +0.03 (+8.40%)
After hours: 07:51PM EDT

Benitec Biopharma Inc.

3940 Trust Way
Hayward, CA 94545
United States
510 780 0819
https://benitec.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees18

Key executives

NameTitlePayExercisedYear born
Dr. Jerel A. Banks M.D., Ph.D.Exec. Chairman & CEO539.96kN/A1975
Ms. Megan Joan Boston BComm, CA, Dip., GAICDExec. Director329.46kN/A1972
Mr. Bryan DulhuntyChief Financial OfficerN/AN/AN/A
Dr. Michael GrahamHead of Discovery & Founding ScientistN/AN/AN/A
Dr. Craig LewisChief Medical AdviserN/AN/AN/A
Dr. Claudia KlothSr. VP of ManufacturingN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Corporate governance

Benitec Biopharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.